Filing Analysis
Humacyte, Inc. filed an 8-K to announce its financial results for the fiscal second quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release and includes the press release as Exhibit 99.1.
📋 Key Facts
- Reporting period: Fiscal second quarter ended June 30, 2026.
- Filing date: August 12, 2026.
- The filing includes a press release regarding financial results (Exhibit 99.1).
- Company is classified as an emerging growth company.
Humacyte, Inc. received a notification from Nasdaq stating that its common stock has been below the $1.00 minimum bid price requirement for 30 consecutive business days as of July 30, 2026. The company has been granted an initial 180-day compliance period ending January 27, 2027.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5450(a)(1) non-compliance).
- Stock price has been consistently below $1.00 for a month, indicating significant downward momentum or fundamental weakness.
- Requirement to achieve a specific closing price over a sustained period (10 consecutive days) presents high execution risk.
📋 Key Facts
- Nasdaq notification received on July 31, 2026.
- The bid price closed below $1.00 for the 30 consecutive business days ended July 30, 2026.
- Compliance period granted until January 27, 2027.
- To regain compliance, the stock must close at $1.00 or more for at least 10 consecutive business days before the deadline.
Humacyte, Inc. entered into an underwriting agreement on June 10, 2026, to sell 47,619,048 shares of common stock at a price of $1.05 per share. The offering is expected to raise approximately $46.80 million in net proceeds, increasing to $53.85 million if the underwriters exercise their over-allotment option.
🚩 Red Flags
- Significant dilution: The issuance of over 47 million shares at a low price point ($1.05) suggests substantial dilution for existing shareholders
- Low share price: A pricing of $1.05 often indicates a distressed valuation or a need for urgent liquidity in micro-cap biotech companies
📋 Key Facts
- Offering size: 47,619,048 firm shares
- Offering price: $1.05 per share
- Expected net proceeds: ~$46.80 million (up to $53.85 million with option)
- Underwriter option: 30-day option to purchase an additional 7,142,857 shares
- Expected closing date: June 12, 2026
- Underwriters: Barclays Capital Inc., BTIG, LLC, and Titan Partners Group LLC
Humacyte, Inc. announced the presentation of Phase 3 clinical trial results (V012) for its acellular tissue engineered vessel (ATEV) specifically for female patients with end-stage renal disease. The company also released an updated investor presentation.
📋 Key Facts
- Phase 3 clinical trial (V012) results presented on June 10, 2026.
- Trial focused on acellular tissue engineered vessel (ATEV) for arteriovenous access in female patients with end-stage renal disease requiring hemodialysis.
- Company released an updated Investor Presentation (Exhibit 99.2) on the same date.
Humacyte, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, where shareholders approved an amendment to the Certificate of Incorporation to significantly increase authorized common stock.
🚩 Red Flags
- Significant increase in authorized shares (approx. 57% increase) often precedes dilutive equity offerings to raise capital.
📋 Key Facts
- Authorized shares of common stock increased from 350,000,000 to 550,000,000 shares.
- The amendment became effective on June 9, 2026.
- Stockholders ratified the appointment of Pricewaterhouse Coopers LLP as the independent auditor for fiscal year ending December 31, 2026.
- Class II directors John P. Bamforth, Keith Anthony Jones, and Kathleen Sebelius were elected.
- Stockholders approved an annual frequency for advisory votes on named executive officer compensation.
Humacyte, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Nasdaq has officially closed the matter regarding the company's listing status.
🚩 Red Flags
- The company recently struggled to maintain the minimum $1.00 share price, indicating significant downward pressure on the stock price in the preceding months.
📋 Key Facts
- The company previously received a deficiency notice on May 4, 2026, because the bid price closed below $1.00 for 30 consecutive business days ended May 1, 2026.
- The company was required to maintain a closing bid price of $1.00 or more for 10 consecutive business days before November 2, 2026.
- On June 5, 2026, Nasdaq notified the company that it has regained compliance and the matter is now closed.
Humacyte, Inc. received a deficiency notice from Nasdaq on May 4, 2026, because its common stock (HUMA) failed to maintain the minimum $1.00 bid price for 30 consecutive business days. The company has 180 days to regain compliance or face potential delisting.
🚩 Red Flags
- Stock price has fallen below the $1.00 threshold, indicating significant market devaluation.
- Potential for a future reverse stock split to artificially inflate the share price for compliance.
📋 Key Facts
- Nasdaq notification received on May 4, 2026, regarding Rule 5450(a)(1) non-compliance.
- Stock price closed below $1.00 for 30 consecutive business days ending May 1, 2026.
- The company has until November 2, 2026, to regain compliance.
- Compliance requires a closing bid price of at least $1.00 for 10 consecutive business days.
- The notice has no immediate effect on the listing or business operations.
Humacyte, Inc. entered into a third amendment with Fresenius Medical Care Holdings, regaining full worldwide rights to its 6mm acellular tissue engineered vessel (HAV). The company previously granted ex-U.S. rights to Fresenius but will now lead global development and commercialization directly.
📋 Key Facts
- On April 21, 2026, Humacyte amended its 2018 Distribution Agreement with Fresenius Medical Care Holdings, Inc.
- Humacyte regained the sole right to develop and commercialize the 6mm acellular tissue engineered vessel-tyod on a worldwide basis.
- Humacyte will pay Fresenius low-single-digit royalties on net sales of the product outside the U.S. following a two-year royalty-free period in each country.
- Existing U.S. royalty obligations to Fresenius remain in place, ranging from mid-single digits to low double digits.
- Fresenius remains obligated to adopt the product as a standard of care in hemodialysis patients where supported by clinical and economic data.
Humacyte, Inc. entered into agreements for a registered direct offering of 25,000,000 shares of common stock at a price of $0.80 per share. The company expects to receive approximately $18.4 million in net proceeds after fees and expenses.
🚩 Red Flags
- Significant potential dilution from the issuance of 25 million new shares.
- The offering price of $0.80 is substantially lower than the $11.50 exercise price of existing warrants mentioned in the filing header, suggesting a significant decline in market valuation.
📋 Key Facts
- Offering of 25,000,000 shares of common stock at $0.80 per share.
- Expected net proceeds of approximately $18,400,000.
- Placement agent is Titan Partners Group LLC (a division of American Capital Partners, LLC).
- The offering is expected to close on or about March 20, 2026.
- The sale is conducted under an existing shelf registration statement on Form S-3 (File No. 333-290231).
Humacyte reported preliminary FY 2025 financial results and announced the suspension of its $60 million ATM equity program. The company also disclosed a $1.48 million purchase commitment from Saudi Arabia for its Symvess product and a new regulatory filing in Israel.
🚩 Red Flags
- Extremely low annual revenue ($2.0 million) relative to the company's cash burn and market stage.
- Suspension of the $60 million ATM program may indicate a shift toward more dilutive or structured financing needs.
- Preliminary financial data is unaudited and subject to final adjustments by PricewaterhouseCoopers LLP.
📋 Key Facts
- Preliminary FY 2025 cash position of approximately $50.9 million as of December 31, 2025.
- Reported preliminary FY 2025 total revenue of $2.0 million, including $1.4 million in product revenue from 61 unit sales of Symvess.
- Suspended and terminated the $60 million At-The-Market (ATM) prospectus with TD Cowen dated December 16, 2025.
- Received a $1.48 million binding purchase commitment from a Saudi Arabian entity for Symvess ATEV units.
- Filed a Marketing Authorization Application (MAA) with the Israel Ministry of Health on March 16, 2026.
- Entered an exclusivity period through July 2, 2026, for joint venture negotiations in Saudi Arabia.
Humacyte, Inc. entered into an 'at-the-market' (ATM) sales agreement with TD Securities (USA) LLC to facilitate the potential sale of up to $60 million in common stock. The proceeds are intended for commercializing Symvess® and funding pipeline development.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- ATM offerings can create downward price pressure as shares are sold into the market over time.
📋 Key Facts
- Entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) on December 16, 2025.
- Aggregate offering size: up to $60,000,000 in common stock.
- The offering will be conducted as an 'at the market' (ATM) offering under Rule 415.
- TD Cowen will receive a commission of up to 3.0% of gross proceeds.
- Proceeds are earmarked for Symvess® commercialization in vascular trauma, pipeline development, and working capital.
Humacyte entered into a $77.5 million senior secured term loan facility with Avenue Venture Opportunities Fund II, L.P., featuring an initial $40 million tranche and two subsequent delayed draw tranches. The agreement includes the issuance of warrants to the lender at a significantly discounted exercise price.
🚩 Red Flags
- High-interest debt (minimum 11.50%) suggests high risk profile for the borrower.
- Significant dilution potential via warrants issued at a deeply discounted price ($1.28 or lower).
- Delayed draw tranches are contingent on 'revenue and regulatory approvals,' creating uncertainty in future capital availability.
- Lender has the right to convert debt into equity, which can lead to further dilution.
📋 Key Facts
- Total facility amount: up to $77,500,000 maturing December 1, 2029.
- First Tranche: $40 million (fully funded on Dec 15, 2025).
- Second Tranche: $12.5 million available Oct 1, 2026 – March 31, 2027, subject to revenue and regulatory conditions.
- Third Tranche: $25 million available July 1, 2027 – June 30, 2028, subject to revenue and regulatory conditions.
- Interest Rate: Greater of 11.50% or WSJ Prime + 4.50%.
- Security: Substantially all company assets are pledged as collateral.
- Warrant Issuance: Lenders received warrants for up to $5,037,500 worth of common stock at an exercise price of the lower of $1.28 or the lowest effective sale price in a bona fide offering through March 31, 2026.
- Conversion Option: Lenders can convert up to $2,500,000 of principal into common stock at 130% of the Warrant Price.
Humacyte, Inc. has terminated a Revenue Interest Purchase Agreement and an Option Agreement with TPC Investments III LP and TPC Investments Solutions LP. To settle these agreements, the company will pay $38 million in cash—to be funded by a new credit facility—and issue 5,725,190 shares of common stock via a registered direct offering.
🚩 Red Flags
- Significant cash outflow ($38M) to terminate previous financing/revenue arrangements.
- Reliance on a new credit facility to fund the termination payment, increasing leverage.
- Issuance of over 5.7 million shares via registered direct offering, which may lead to shareholder dilution.
📋 Key Facts
- Termination of Revenue Interest Purchase Agreement and Option Agreement dated May 12, 2023.
- Cash consideration for termination: $38 million.
- Equity consideration for termination: 5,725,190 shares of common stock via registered direct offering.
- The $38 million cash payment is expected to be funded by a new credit facility.
- The equity issuance is being conducted under an existing shelf registration (File No. 333-290231) declared effective on Sept 22, 2025.
Humacyte, Inc. has terminated its Open Market Sale Agreement with Jefferies LLC, which was originally established on September 1, 2022.
🚩 Red Flags
- Termination of a large-scale ($80M) equity sale facility could suggest the company no longer requires immediate liquidity via this specific mechanism or has secured alternative financing/cash flow.
📋 Key Facts
- The Company terminated the Open Market Sale Agreement with Jefferies LLC on November 21, 2025.
- The termination will become effective 10 days after notice delivery (approx. December 1, 2025).
- The original agreement allowed for the sale of common stock up to an aggregate price of $80,000,000.
- Humacyte is not subject to any termination penalties related to this cancellation.
Humacyte, Inc. filed an 8-K to announce its financial results for the fiscal third quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings press release.
📋 Key Facts
- Reporting period: Fiscal third quarter ended September 30, 2025.
- Filing date: November 12, 2025.
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Humacyte, Inc. entered into a securities purchase agreement for a registered direct offering of 28,436,018 shares of common stock and an equal number of warrants at a price of $2.11 per share/warrant. The offering is expected to close on October 8, 2025.
🚩 Red Flags
- Significant dilution potential due to the issuance of nearly equal numbers of warrants as shares (1:1 warrant coverage).
- Warrant exercise price ($2.11) is significantly lower than the $11.50 mentioned in the header/XBRL metadata, suggesting heavy discounting or complex structure.
- High placement agent fees and 'tail financing' provisions.
📋 Key Facts
- Offering size: 28,436,018 shares of Common Stock and 28,436,018 Warrants.
- Pricing: $2.11 per share and $2.11 per warrant.
- Warrant terms: Exercisable 180 days after issuance; expire April 7, 2031.
- Placement Agent: D. Boral Capital LLC (5.75% fee + up to $100,000 expense reimbursement).
- Tail Financing: Placement agent entitled to 6.0% of gross proceeds from certain financing for 6-12 months post-agreement.
- Lock-up/Restriction: Company cannot issue common stock or enter variable rate transactions for 30 days.
Humacyte, Inc. entered into an amendment to its Revenue Interest Purchase Agreement as part of a debt refinancing plan. The amendment involves a $50 million repayment and provides the company with an option to repurchase the interest at a discounted price of $95.5 million by year-end 2025.
🚩 Red Flags
- Refinancing activity suggests active management of debt obligations/liquidity.
- Complexity of revenue interest purchase agreements can impact future cash flows.
📋 Key Facts
- Amendment No. 2 to Revenue Interest Purchase Agreement entered into on September 17, 2025.
- Company will make a $50.0 million repayment using restricted cash currently held for the Agent.
- Requirement to maintain $50.0 million in restricted cash is waived unless the agreement isn't repaid by Dec 31, 2025; if not repaid, $12.5 million must be maintained.
- Company has a call option to repurchase at a discounted price of $95.5 million if exercised by December 31, 2025.
- Up to $7.5 million of the repurchase may be satisfied via issuance of common stock.
Humacyte, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal second quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 11, 2025
- Reporting period: Fiscal second quarter ended June 30, 2025
- The filing is a standard earnings release announcement (Item 2.02)
- Company is an emerging growth company
Humacyte, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025. The meeting resulted in the election of four Class I directors and the approval of an amendment to increase authorized common stock shares.
🚩 Red Flags
- Increase in authorized share count (from 250M to 350M) can lead to future dilution if used for equity financing.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Stockholders approved increasing authorized common stock from 250,000,000 to 350,000,000 shares (Proposal 3).
- Four Class I directors were elected: Brady W. Dougan, C. Bruce Green, Diane Seimetz, and Max Wallace.
- Pricewaterhouse Coopers LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Quorum was established with approximately 63.1% of shares (97,879,466 shares) present.
Humacyte, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal first quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Fiscal first quarter ended March 31, 2025
- The filing serves to furnish Exhibit 99.1 (Press Release) regarding financial results.
- Company is an emerging growth company.
Humacyte, Inc. filed an 8-K to furnish a statement regarding 'Recent Attacks' dated April 17, 2025. The filing does not contain standard financial disclosures but refers to an external statement in Exhibit 99.1.
🚩 Red Flags
- Mention of 'Recent Attacks' suggests potential operational, cybersecurity, or physical security disruptions that may impact business continuity.
📋 Key Facts
- Report date: April 17, 2025
- The company issued a statement regarding 'Recent Attacks' via Exhibit 99.1
- Filing is categorized under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits)
Humacyte, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Reporting period: Fiscal fourth quarter and full year ended December 31, 2024.
- Filing date: March 28, 2025.
- The filing is a standard earnings release under Item 2.02.
Humacyte, Inc. filed an 8-K to furnish a statement regarding a New York Times article published on March 27, 2025. The filing is primarily for regulatory compliance under Item 7.01 (Regulation FD Disclosure).
📋 Key Facts
- Filing date: March 27, 2025.
- The company is an emerging growth company.
- The purpose of the filing is to furnish a statement in response to a New York Times article dated March 27, 2025 (Exhibit 99.1).
- The information provided under Item 7.01 is considered 'furnished' rather than 'filed' for purposes of Section 18 of the Exchange Act.
Humacyte, Inc. entered into an underwriting agreement to conduct a public offering of 25 million shares of common stock at $2.00 per share. The offering aims to raise approximately $46.6 million in net proceeds.
🚩 Red Flags
- Significant dilution: Issuance of 25 million new shares at a price of $2.00 per share represents substantial equity dilution for existing shareholders.
- Urgent capital need: The scale of the offering suggests a significant requirement for immediate liquidity/working capital.
📋 Key Facts
- Underwriting Agreement dated March 25, 2025.
- Offering size: 25,000,000 firm shares at $2.00 per share.
- Over-allotment option: Up to 3,750,000 additional shares.
- Expected net proceeds: ~$46.6 million (or ~$53.7 million if option is exercised).
- Underwriters include TD Securities (USA) LLC, Barclays Capital Inc., and BTIG, LLC.
- Offering expected to close on March 27, 2025.
- The offering is being conducted under an existing S-3 shelf registration.
Humacyte, Inc. filed an 8-K to announce the release of a new investor presentation dated March 25, 2025, intended for use in future investor calls and conferences.
📋 Key Facts
- The company released an updated Investor Presentation (Exhibit 99.1).
- The filing is categorized under Item 8.01 (Other Events).
- The presentation is intended for use in upcoming investor relations activities.
Humacyte, Inc. announced that the FDA has granted full approval for its SYMVESS™ acellular tissue engineered vessel for use in adults as a vascular conduit for extremity arterial injury.
📋 Key Facts
- FDA granted full approval for SYMVESS™ (acellular tissue engineered vessel).
- Indication: Use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and autologous vein graft is not feasible.
- Announcement date: December 19, 2024.
Humacyte, Inc. entered into a securities purchase agreement for a registered direct offering of 2,808,988 shares of common stock and an equal number of warrants at a price of $5.34 per share/warrant combo.
🚩 Red Flags
- Dilution risk due to issuance of significant new shares and warrants.
- Warrant overhang: Nearly 2.8M warrants are exercisable at $5.34, which may create downward pressure on the stock price upon exercise.
📋 Key Facts
- Offering size: 2,808,988 shares of Common Stock and 2,808,988 Warrants.
- Pricing: $5.34 per Share and accompanying Warrant.
- Warrant terms: Exercise price of $5.34; half expire in 180 days, the other half expire in 1,640 days.
- Ownership limit: Warrants cannot be exercised if it results in beneficial ownership exceeding 4.99% (or up to 9.99% by election) for certain parties.
- Expected closing date: November 15, 2024.
- Standstill provision: Company is restricted from issuing common stock or entering variable rate transactions until FDA approval of acellular tissue engineered vessel for extremity vascular trauma or 30 days after the agreement (whichever is earlier).
Humacyte, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal third quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 8, 2024
- Reporting period: Fiscal third quarter ended September 30, 2024
- The filing is a standard earnings release announcement (Item 2.02)
- Includes Exhibit 99.1 containing the press release
Humacyte, Inc. announced positive Phase 3 clinical trial results for its acellular tissue engineered vessel (ATEV) in arteriovenous access for end-stage renal disease patients. The announcement was made during the American Society of Nephrology’s Kidney Week 2024.
📋 Key Facts
- Positive Phase 3 clinical trial (V007) results announced on October 28, 2024.
- Trial focused on acellular tissue engineered vessel (ATEV) for arteriovenous access in end-stage renal disease patients.
- Results presented at the American Society of Nephrology’s Kidney Week 2024.
Humacyte, Inc. entered into a securities purchase agreement for a registered direct offering of 5,681,820 shares of common stock and an equal number of warrants at a price of $5.28 per share/warrant combo.
🚩 Red Flags
- Significant dilution potential due to the issuance of nearly 5.7 million warrants.
- The offering price ($5.28) represents a significant discount if compared to historical trading ranges (though specific market price at time of filing is not in text, such offerings often imply immediate liquidity needs).
- Warrant expiration structure: A large block of warrants expires in only 180 days, which can create short-term downward pressure on the stock.
📋 Key Facts
- Offering Type: Registered direct offering via shelf registration (Form S-3).
- Total Shares to be issued: 5,681,820 shares of Common Stock and 5,681,820 Warrants.
- Pricing: $5.28 per share and accompanying warrant.
- Warrant Terms: Exercise price of $5.28; half expire in 180 days, the other half expire in 1,640 days.
- Placement Agent: EF Hutton LLC (6.0% fee + up to $100,000 expense reimbursement).
- Closing Date: Expected October 7, 2024.
Humacyte entered into a $50 million equity line of credit (purchase agreement) with Lincoln Park Capital Fund, LLC. This allows the company to sell common stock at a discount to market prices over a 24-month term.
🚩 Red Flags
- Equity line of credit/At-the-market offering structure often leads to significant shareholder dilution.
- The 97% discount to market price ensures immediate downward pressure on the share price upon execution of sales.
- The agreement includes a 'Floor Price' of $1.00, which may indicate management's concern regarding maintaining minimum listing requirements or stock value.
📋 Key Facts
- Entered into a purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC on September 24, 2024.
- Aggregate value of shares to be sold is up to $50,000,000.
- The company can direct sales at its sole discretion over a 24-month term.
- Purchase price per share is 97% of the lesser of: the lowest sale price on the purchase date or the average of the three lowest closing prices over the preceding 10 business days.
- A 'Floor Price' of $1.00 per share is established for regular purchases.
- The company issued 115,705 shares to Lincoln Park as a commitment fee (no cash proceeds received).
- Lincoln Park is prohibited from short-selling or hedging the common stock during the term.
Humacyte announced that the FDA requires additional time to complete its review of the Biologics License Application (BLA) for its acellular tissue engineered vessel in the vascular trauma indication. The company also released its fiscal second quarter 2024 financial results.
🚩 Red Flags
- Regulatory delay for a core product candidate (acellular tissue engineered vessel) which is critical for a biotech company's valuation and path to commercialization.
📋 Key Facts
- FDA delay: Review of BLA for acellular tissue engineered vessel (vascular trauma indication) will take longer than originally anticipated.
- Financial Results: Company issued Q2 2024 financial results on August 13, 2024.
- Reporting Period: Fiscal second quarter ended June 30, 2024.
Humacyte, Inc. announced positive top-line results from its Phase 3 clinical trial (V007) regarding its acellular tissue engineered vessel (ATEV) for patients with end-stage renal disease.
📋 Key Facts
- Positive top-line results reported from Phase 3 clinical trial (V007).
- Trial focus: ATEV in arteriovenous access for end-stage renal disease patients.
- Filing date: July 31, 2024.
Humacyte, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 11, 2024. The meeting resulted in the election of six Class III directors and the ratification of Pricewaterhouse Coopers LLP as the independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on June 11, 2024, with a quorum of approximately 58.8% (70,031,441 shares).
- Six Class III directors were elected: John P. Bamforth, Emery N. Brown, Michael T. Constantino, Keith Anthony Jones, Laura E. Niklason, and Susan Windham-Bannister.
- Drs. Bamforth and Jones resigned from Class III to be re-appointed as Class II directors to achieve board class balance; service is deemed continuous for all purposes.
- Pricewaterhouse Coopers LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
Humacyte, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal first quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 10, 2024
- Reporting period: Fiscal first quarter ended March 31, 2024
- The filing is a standard earnings release announcement (Item 2.02)
- Company is classified as an 'emerging growth company'
Humacyte, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Report date: March 22, 2024
- Reporting period: Fiscal fourth quarter and full year ended December 31, 2023
- The filing is primarily to furnish Exhibit 99.1 (Press Release) regarding financial results.
- Company identifies as an 'emerging growth company'.
Humacyte, Inc. entered into an underwriting agreement to conduct a public offering of 13.4 million shares of common stock at $3.00 per share. The offering aims to raise approximately $37.4 million in net proceeds to fund company operations.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of 13.4 million new shares.
- The offering price of $3.00 per share may be at a significant discount to recent market prices (implied by typical micro-cap/growth biotech financing patterns), suggesting urgent need for capital.
📋 Key Facts
- Offering size: 13,400,000 firm shares plus a 30-day option for underwriters to purchase up to 2,010,000 additional shares.
- Offering price: $3.00 per share.
- Expected net proceeds: Approximately $37.4 million (or $43.1 million if the over-allotment option is exercised in full).
- Underwriters: Cowen and Company, LLC and Cantor Fitzgerald & Co. acting as representatives.
- Closing date: Expected March 5, 2024.
- Registration basis: Effective shelf registration statement on Form S-3 (File No. 333-267225).
Humacyte, Inc. released an updated investor presentation to be used for upcoming investor calls and conferences. The filing does not contain material financial changes or structural corporate shifts.
📋 Key Facts
- Company released a new Investor Presentation dated February 29, 2024.
- The presentation is intended for use in investor calls and/or conferences.
- The company is classified as an 'emerging growth company' under SEC rules.
Humacyte, Inc. announced that the FDA has granted Priority Review to its Biologics License Application (BLA) for its human acellular vessel intended for urgent arterial repair in extremity vascular trauma.
📋 Key Facts
- FDA granted Priority Review for the Company's Biologics License Application (BLA).
- The application is for a human acellular vessel used in urgent arterial repair following extremity vascular trauma.
- Indication: When synthetic grafts are not indicated and autologous vein use is not feasible.
- Filing date: February 9, 2024.